Felodipine Tablet, Film Coated
Product Images NDC 72162-1744

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 72162-1744). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (1 Formula)

Image Description (1 Formula)
FDA Label Image

Label (Lbl721621744)

Label (Lbl721621744)
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
Mean reductions in blood pressure were measured in two different studies. In Study 1, at doses of 25mg, 5mg, and 10mg, the mean reductions in systolic blood pressure were 947mmHg, 950mmHg, and 181mmHg, respectively. The mean reductions in diastolic blood pressure were 271mmHg, 245mmHg, and 100mmHg, respectively. Study 2, which lasted for 4 weeks, included a dose of 20mg, resulting in mean reductions of 537mmHg for systolic blood pressure and 455mmHg for diastolic blood pressure. It is worth noting that the number of patients available for peak and trough measurements varied between the studies.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
Percent of Patients with Adverse Events in Controlled Trials of Felodipine Extended-Release Tablets: - Body System: - Placebo: Peripheral Edema (33%), Asthenia (33%), Warm Sensation (0%), Palpitation (24%), Nausea (15%), Dyspepsia (12%), Constipation (9%), Headache (102%), Dizziness (27%), Paresthesia (15%), Upper Respiratory Infection (1.8%), Cough (0%), Rhinorthea (0%), Sneezing (0%), Rash (9%), Flushing (9%) - 25mg: Peripheral Edema (2%), Asthenia (39%), Warm Sensation (0%), Palpitation (4%), Nausea (12%), Dyspepsia (39%), Constipation (12%), Headache (106%), Dizziness (27%), Paresthesia (16%), Upper Respiratory Infection (39%), Cough (8%), Rhinorthea (16%), Sneezing (16%), Rash (2%), Flushing (39%) - 5mg: Peripheral Edema (88%), Asthenia (33000), Warm Sensation (09%), Palpitation (14%), Nausea (17%), Dyspepsia (07%), Constipation (03%), Headache (11%), Dizziness (36%), Paresthesia (12000), Upper Respiratory Infection (19000), Cough (12000), Rhinorthea (02%), Sneezing (0%), Rash (02%), Flushing (53%) - 10mg: Peripheral Edema (174%), Asthenia (22%), Warm Sensation (15%), Palpitation (25%), Nausea (1%), Dyspepsia (5%), Constipation (15%), Headache (147%), Dizziness (37%), Paresthesia (12002), Upper Respiratory Infection (07%), Cough (17%), Rhinorthea (02%), Sneezing (0%), Rash (02%), Flushing (69%) Note: Percentages shown in parentheses indicate the incidence of discontinuations. Please note that patients in titration studies may have been exposed to more than one dose level of felodipine extended-release tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.